Compare Summit Therapeutics Inc (SMMT) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Summit Therapeutics Inc trades at $17.55 (market cap $13.79B), while Vanguard Intermediate Term Corporate Bond ETF trades at $80.48. The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| SMMT | VCIT | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | Fixed Income |
52-Week High | $26.38 | $84.82 |
52-Week Low | $12.43 | $80.31 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
VCIT trades at $80.46, down 0.09% on the day, with a bearish technical signal from moving averages but bullish oscillators. The ETF offers a 4.8% yield and low 0.03% expense ratio, attracting institutional interest as seen with HB Wealth Management increasing holdings by 242.9% in Q3 2026 (SEC filing, September 2026). Recent news highlights its competitive edge in intermediate-term corporate bonds.
The outlook remains favorable for income investors seeking yield with moderate risk, though bearish momentum and interest rate sensitivity pose near-term headwinds. Key opportunities include cost efficiency and diversification, while risks involve market volatility and economic shifts affecting corporate credit.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
